Loading…
Employees: 1,621
Size Teyi Pharmaceutical (002728.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $465M, the 4036th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥9.02 on 6 Nov 2026.
Performance Over six months the shares fell 9.2%, against -19.7% for the median peer and -16.4% for the China market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue fell 7.3% over the last twelve months (peer median -4.9%); the operating margin is 7.4% (peer median 2.3%).
Valuation It trades at 31.1× forward earnings against a peer median of 16.9× (most expensive of 5).
Price implies For today's price to make sense, revenue must grow about 27% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.0 points below its cost of capital (12.2% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥856M | CN¥916M | CN¥685M | CN¥1.06B | CN¥881M |
| Revenue growth | — | +34% | -35% | +20% | — |
| Gross profit | CN¥497M | CN¥466M | CN¥269M | CN¥563M | CN¥403M |
| EBITDA | n/a | CN¥147M | CN¥91.2M | CN¥367M | CN¥262M |
| Net income | CN¥65.9M | CN¥81.7M | CN¥20.5M | CN¥253M | CN¥178M |
| Free cash flow | CN¥51.2M | CN¥165M | -CN¥132M | CN¥113M | CN¥282M |
| Capital expenditure | CN¥71.7M | CN¥79.5M | CN¥114M | CN¥86.0M | CN¥90.3M |
| Total debt | CN¥403M | CN¥277M | CN¥526M | CN¥347M | CN¥899M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002728.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.3% | -11.4% | 8th highest of 20 |
| 6-month return | -9.2% | -19.7% | 7th highest of 20 |
| Distance from 52-week high | -40.7% | -41.5% | 10th highest of 20 |
| Revenue growth (TTM) | -7.3% | -4.9% | 10th lowest of 21 |
| Operating margin | 7.4% | 2.3% | 8th highest of 21 |
| Forward P/E | 31.1× | 16.9× | most expensive of 5 |
| Growth the price implies (Req g, 7 yrs) | 26.6% | 7.1% | 4th most demanding of 10 |
| Growth delivered (Del g) | +8.0% | +0.7% | 2nd highest of 10 |
| Hurdle (Req g minus delivered) | +18.6 pp | +3.8 pp | 4th most demanding of 10 |
| ROIC minus cost of capital | -7.0 pp | -1.6 pp | 6th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Teyi Pharmaceutical 002728.SZ | China | $465M | -9% | -7% | 7% | 31.1× | 26.6% | +8.0% |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $466M | -20% | -21% | -68% | n/a | n/a | n/a |
| Evonile Pharma EVONILE.NS | India | $466M | n/a | -5% | 12% | n/a | 46.5% | -1.5% |
| Shanghai Jiaoda Onlly 600530.SS | China | $464M | -22% | -2% | -2% | n/a | 33.5% | -0.9% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $467M | -13% | -5% | -29% | n/a | n/a | n/a |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $464M | -30% | +14% | 5% | n/a | 2.5% | -1.3% |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $463M | -21% | +7% | 19% | n/a | 7.1% | +1.3% |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $470M | -39% | +35% | 4% | 11.1× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $470M | -38% | -14% | -12% | 25.1× | n/a | n/a |
| Cachet Pharmaceutical 002462.SZ | China | $471M | -22% | -14% | 0% | n/a | -8.9% | -3.4% |
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | n/a | -4.9% | +0.7% |
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 21.0× | 5.7% | +3.3% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | n/a | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $476M | -10% | +40% | 13% | n/a | 44.5% | +1.0% |
| Beijing Foyou Pharma 601089.SS | China | $455M | -24% | +5% | 10% | 12.8× | n/a | n/a |
| Gufic Biosciences GUFICBIO.NS | India | $454M | +44% | +17% | 14% | n/a | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $454M | -16% | +13% | -114% | n/a | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $477M | +62% | +10,947% | -194% | n/a | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $477M | -45% | -87% | -477% | n/a | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $450M | -4% | -14% | -34% | n/a | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $450M | +4% | -21% | 8% | n/a | 23.7% | +28.2% |